1607793-29-2
Chemical Structure
Faricimab
Synonym(s): RG7716; RO-6867461
- CAS No.: 1607793-29-2
- Formula:N/A
- Molecular Weight:(146.16 kDa)
IUPAC Name: 2-(benzyloxy)-6-bromoquinoline-5-carbonitrile
SMILES: [Faricimab]
Biological Activity: Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO)[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Faricimab | 97.97% | Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170. [Content Brief]
- [2]. Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. [Content Brief]
- [3]. Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10(1):5. [Content Brief]
- [4]. Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464. [Content Brief]
- [5]. Jørstad ØK, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9(1):65. [Content Brief]
Keywords
